Profile

Dr. Jacqueline Houtman

Science Editorial Lead, The Pandemic Tracking Collective

Jacqueline Houtman’s doctoral research investigated the immune response to a coronavirus in a mouse model for multiple sclerosis. She participated in the Data Entry and Science Communication teams at The COVID Tracking Project at The Atlantic. As a freelance biomedical science writer and editor, she worked with organizations including the University of Wisconsin School of Medicine and Public Health, FASEB, The Dana Foundation, and The National Hemophilia Foundation. She is an award-winning author of books for young people.

Dr. Houtman received a BA in Biological Sciences and an MS in Animal Science from the University of Delaware, as well as a PhD in Medical Microbiology and Immunology from the University of Wisconsin-Madison.

Authored Content

  • Jun 06 2022
    Blueprint The Challenge of Measuring Vaccine Effectiveness In mid-November 2020, as Covid-19 cases were rising and two thousand people were dying every day in the U.S., Americans needed hope. They got it. Hope arrived in a syringe. Effective vaccines were developed in record time, with the promise of ending the current pandemic. The scientific discoveries behind that quick vaccine development are also […] Dave Luo, Jacqueline Houtman, Lindsey Shultz, Samuel Scarpino
  • Apr 05 2022
    Blog Post A User’s Guide to U.S. Vaccine Breakthrough Rates With the United States over a year into its vaccination campaign, all eyes right now are on Covid-19 rates broken out by vaccination status—measures of the number of Covid-19 cases, hospitalizations, and deaths per 100,000 vaccinated or unvaccinated individuals. Shared by the U.S. Centers for Disease Control and Prevention (CDC) as well as many state, […] Dave Luo, Jacqueline Houtman, Jessica Malaty Rivera, Jonathan Gilmour, Kaitlyn Johnson, Kara Schechtman, Leo Wolansky, Lindsey Shultz, Rebecca Glassman
  • Mar 25 2022
    Blueprint Variants, Sublineages, and Recombinants: The Constantly Changing Genome of SARS-CoV-2 During the course of the Covid-19 pandemic, numerous variants of SARS-CoV-2 have emerged. Some have died out, and some have surged globally. They are all SARS-CoV-2, but they differ in important ways. Think of them as the boughs of the SARS-CoV-2 family tree, each of which has branched off into many smaller limbs. The smaller […] Dave Luo, Dr. Rick Bright, Jacqueline Houtman, Jessica Malaty Rivera, Jonathan Gilmour, Lindsey Shultz, Samuel Scarpino
  • Feb 16 2022
    Blueprint Tracking SARS-CoV-2 and Its Variants in Wastewater: An Old Technique Is Yielding Powerful New Insights in the Covid-19 Pandemic The newest addition to the Centers for Disease Control and Prevention’s (CDC) Covid Data Tracker reports on levels of SARS-CoV-2 RNA in wastewater. While researchers, public health departments, and some private companies have been monitoring wastewater since the beginning of the pandemic, this tracker marks an important step in the establishment of the National Wastewater Surveillance System […] Dave Luo, Dr. Rick Bright, Jacqueline Houtman, Jessica Malaty Rivera, Jonathan Gilmour, Lindsey Shultz, Megan Diamond
  • Dec 28 2021
    Field Note Vaccine Inequity Increases the Risk of New SARS-CoV-2 Variants Emerging Robust genomic surveillance, along with transparency, communication, and global collaboration, is needed to detect and control emerging variants. To control the Covid-19 pandemic, the World Health Organization (WHO) called on member states to meet a goal of vaccinating 40% of their population by the end of 2021. As of mid December 2021, over 8.6 billion […] Dave Luo, Dr. Rick Bright, Emily Bass, Jacqueline Houtman, Jessica Malaty Rivera, Jonathan Gilmour, Lindsey Shultz
Back to Top